TrialEuropean heart journal2016

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study.

John J P Kastelein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.